Indications
RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
Composition
- Active substance
- lasmiditan succinate
- International name (INN)
- lasmiditan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rayvow
- Active substance
- lasmiditan succinate
- ATC code
- N02CC08
- Group
- Nervous system
- Therapeutic area
- Migraine Disorders
- Marketing authorisation holder
- Eli Lilly Nederland B.V.
- Status
- Authorised
- EU authorisation